SCHEMBL6209558

SCHEMBL6209558

O=C(c1ccc(F)cc1)C1CCN(C(=O)Nc2ccc(F)cc2)CC1

nearest known ligand 0.88

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 4/20 0.81
CYP2C9 P11712 3/20 0.81
CYP1A2 P05177 2/20 0.81
GAA P10253 1/20 0.81
KMT2A Q03164 4/20 0.72
MEN1 O00255 1/20 0.72
HSD11B1 P28845 2/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
SMN1; SMN2 Q16637 2/20 0.66
ALDH1A1 P00352 2/20 0.66
LMNA P02545 1/20 0.66
HTT P42858 1/20 0.66
POLB P06746 1/20 0.66
HSD17B10 Q99714 1/20 0.65
GLA P06280 1/20 0.63
MAPK1 P28482 1/20 0.63
BLM P54132 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13873393 0.88 CYP2C9 (0.76) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL6212293 0.86 CYP2C9 (0.88) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL6349679 0.84 CYP2C9 (0.61) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL12184237 0.84 CYP2C19 (0.70) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL12529097 0.83 CYP2C19 (0.62) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL6210925 0.82 KDM4E (0.71) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL6211538 0.81 CYP1A2 (0.78) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL14047979 0.81 NPC1 (0.61) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL7470383 0.81 KMT2A (0.67) CYP2C19CYP2C9CYP1A2GAAKMT2A
SCHEMBL11839197 0.81 SMN1; SMN2 (0.68) CYP2C19CYP2C9CYP1A2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1723199-A 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors ASTRAZENECA AB (SE) 2006-01-18 CN disclosed
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1556349-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS Astrazeneca AB (SE) 2005-07-27 EP disclosed
WO-2004033427-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS ASTRAZENECA AB (SE) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors HSD11B1, HSD3B1, P4HA1 CYP2C19 462/4885CYP2C9 482/4885CYP1A2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.